Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

The FDA Has Granted Breakthrough Therapy Designation To Alector/GSK's Latozinemab, An Investigational Human Monoclonal Antibody Designed To Block Sortilin To Elevate Progranulin Levels For To Treat Frontotemporal Dementia With A Progranulin Gene Mutation

Author: Benzinga Newsdesk | February 07, 2024 08:12am

Posted In: ALEC GSK